Haemocomplettan P

Haemocomplettan P is a prescription‑only plasma‑derived medication whose active ingredient is human fibrinogen. It is supplied as a sterile solution for intravenous injection and is marketed throughout the European Union. The product is used to replace deficient fibrinogen in patients with congenital or acquired fibrinogen deficiency and during massive hemorrhage to restore normal clot formation. This therapy assists clinicians in achieving rapid hemostasis when conventional blood products are insufficient.

Haemocomplettan P is indicated for several clinical situations where fibrinogen replacement is required.

- Congenital fibrinogen deficiency (afibrinogenemia, hypofibrinogenemia) to prevent or treat bleeding episodes. - Acquired hypofibrinogenemia associated with liver disease, massive transfusion, or disseminated intravascular coagulation. - Massive hemorrhage during surgery or trauma when rapid fibrinogen supplementation is needed. - Cardiopulmonary bypass or extracorporeal membrane oxygenation procedures where fibrinogen levels may fall. - Obstetric hemorrhage, such as postpartum bleeding, when fibrinogen levels are low. - Bleeding complications in patients with inherited coagulation disorders who have secondary fibrinogen depletion.

The safety profile of Haemocomplettan P reflects the typical reactions observed with plasma‑derived fibrinogen products.

Common: - Mild fever or chills during or after infusion. - Transient headache or dizziness. - Nausea or mild gastrointestinal discomfort. - Local infusion site reactions such as erythema or mild swelling. - Transient hypotension or mild tachycardia during infusion. - Mild fatigue or feeling of weakness after administration.

Serious: - Allergic reactions including urticaria, bronchospasm, or anaphylaxis. - Thromboembolic events such as deep‑vein thrombosis or pulmonary embolism. - Volume overload, particularly in patients with cardiac failure. - Disseminated intravascular coagulation exacerbation. - Renal impairment or acute kidney injury in susceptible individuals. - Severe bleeding due to uncontrolled coagulopathy unrelated to fibrinogen deficiency.

When prescribing Haemocomplettan P, clinicians should consider several precautionary measures to ensure safe use.

- Assess baseline fibrinogen level and overall coagulation status before administration. - Use caution in patients with a history of thromboembolic disease or active clot formation. - Monitor for signs of allergic reaction during and after infusion, especially in individuals with prior plasma product sensitivities. - Evaluate cardiac function and fluid status to avoid volume overload in patients with heart failure. - Avoid use in patients with uncontrolled disseminated intravascular coagulation until the underlying condition is managed. - Consider renal function; adjust dosing or monitoring in severe renal impairment.

Haemocomplettan P may interact with other agents that affect coagulation or hemodynamics.

Avoid: - Concomitant use of pro‑coagulant agents (e.g., activated factor VII) that could increase thrombotic risk. - High‑dose anticoagulants (e.g., unfractionated heparin, direct thrombin inhibitors) administered immediately before fibrinogen infusion without appropriate monitoring. - Concurrent administration of fibrinolytic agents (e.g., alteplase) may counteract the hemostatic effect of fibrinogen replacement.

Use with caution: - Antifibrinolytic drugs (e.g., tranexamic acid) as combined therapy may enhance clot stability. - Other plasma‑derived products (e.g., cryoprecipitate, factor concentrates) to prevent excessive fibrinogen levels. - Medications that cause fluid retention or affect cardiac output (e.g., certain antihypertensives) in patients at risk of volume overload.